Chadi Hage Chehade

397 posts

Chadi Hage Chehade banner
Chadi Hage Chehade

Chadi Hage Chehade

@chadihcmd

PGY1 @UofUInternalMed Former Post-Doctoral Research Fellow @Huntsmancancer @UUtah 🇺🇸 MD 23' @usjliban 🇱🇧🇫🇷

Salt Lake City, Utah Katılım Ağustos 2023
346 Takip Edilen344 Takipçiler
Chadi Hage Chehade retweetledi
UroToday.com
UroToday.com@urotoday·
Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX
UroToday.com tweet media
English
1
3
11
1.5K
Chadi Hage Chehade retweetledi
Umang Swami, MD, MSCI, FASCO
Umang Swami, MD, MSCI, FASCO@umangtalking·
Excited to be part of @Uromigos LIVE & UnpluggD ‘25! Can’t wait for the lively, engaging, unfiltered, and insightful conversations that make this meeting so special @OncoAlert
Umang Swami, MD, MSCI, FASCO tweet mediaUmang Swami, MD, MSCI, FASCO tweet mediaUmang Swami, MD, MSCI, FASCO tweet mediaUmang Swami, MD, MSCI, FASCO tweet media
English
0
12
17
2.6K
Chadi Hage Chehade retweetledi
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
Voting for the ASCO election is now open! I am honored to be running as one of the candidates for the @ASCO Nominating Committee seat. Visit asco.org/election to learn more about the candidates and place your vote! Thank you!!
Neeraj Agarwal, MD, FASCO tweet media
English
20
99
243
147.6K
Chadi Hage Chehade retweetledi
Umang Swami, MD, MSCI, FASCO
Umang Swami, MD, MSCI, FASCO@umangtalking·
Proud to endorse my mentor and friend @neerajaiims for the @ASCO Nominating Committee! His humility, kindness, unwavering dedication to mentoring young investigators globally & advancing cancer research inspire me every day. A true leader who lifts everyone around him.
Umang Swami, MD, MSCI, FASCO tweet media
English
1
12
26
2.5K
Chadi Hage Chehade retweetledi
UroToday.com
UroToday.com@urotoday·
Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX
UroToday.com tweet media
English
0
3
10
1.1K
Chadi Hage Chehade retweetledi
UroToday.com
UroToday.com@urotoday·
Delayed genomic testing limits access to life-prolonging cancer treatments. @chadihcmd @huntsmancancer joins @neerajaiims to discuss the utilization of next-generation sequencing in nearly 200,000 patients with common cancers having approved targeted therapies. #WatchNow on UroToday > bit.ly/4fOR7EX
UroToday.com tweet media
English
1
7
16
1.4K
Chadi Hage Chehade retweetledi
Medical.watch
Medical.watch@MedicalwatchHQ·
🌟🌎 #GlobalGUFriday 🧬 PARP inhibitors: from ovarian cancer to a pan-tumor approach — Landmark phase III trials transforming care in HRR-mutated tumors. @chadihcmd @ggebraelmd @nsayeghmd @ziremozay @SWOGadvocate @JenniferLitton @umangtalking @neerajaiims 📌 FDA/EMA approvals based on pivotal data: 🟣 Ovary – SOLO-1/2, PRIMA, PAOLA-1, ARIEL3 (maintenance & 1L combo) 🩷 Breast – OlympiA, EMBRACA (gBRCA early & metastatic) 🟡 Prostate – PROfound, PROpel, MAGNITUDE, TALAPRO-2 (mCRPC) 🟢 Pancreas – POLO (gBRCA mPDAC maintenance) 💡 Mechanism: Exploits DNA repair defects → synthetic lethality 📈 Benefit: OS & PFS gains across tumor types 🔍 Trends: Expanding into combinations (IO, ADCs), early stages, and basket trials 💡 Main messages: 1️⃣ Synthetic lethality is now a validated therapeutic principle across tumor types. 2️⃣ HRR testing (BRCA1/2, ATM, PALB2…) should be integrated into routine work-up. 3️⃣ Maintenance strategies prolong disease control and delay chemo. 4️⃣ Combinations with IO & ADCs may expand benefit beyond BRCA+ disease. 🩺 Clinical implications: ✔ Test early → identify candidates before progression. ✔ Cross-tumor genomic panels are now standard in advanced disease. ✔ Watch for hematologic toxicity, fatigue & GI AEs — require proactive management. @OncoAlert @APCCC #PARPinhibitors #DNArepair #PrecisionOncology #OncoTwitter #Medicalwatch pubmed.ncbi.nlm.nih.gov/39791278/
Medical.watch tweet mediaMedical.watch tweet mediaMedical.watch tweet media
English
2
6
12
860
Chadi Hage Chehade retweetledi
ASCO
ASCO@ASCO·
Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu
ASCO tweet mediaASCO tweet mediaASCO tweet media
English
1
21
103
63K
Chadi Hage Chehade retweetledi
Neeraj Agarwal, MD, FASCO
Neeraj Agarwal, MD, FASCO@neerajaiims·
Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert
Neeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet mediaNeeraj Agarwal, MD, FASCO tweet media
Neeraj Agarwal, MD, FASCO@neerajaiims

Just in👉Two @TheLancetOncol papers on patient-reported QOL results in ph3 TALAPRO-2 trial👉in all-comer & HRR deficient mCRPC #ProstateCancer pts👉Improved OS without compromising QOL👇Links: bit.ly/3DWHlSR & bit.ly/3E3SSQi @urotoday @OncoAlert @PCFnews 👇

English
18
68
180
35.8K
Chadi Hage Chehade retweetledi
HemOnc Today
HemOnc Today@HemOncToday·
Real-world data show that only 30% to 40% of patients with the most common cancers receive NGS testing. 🗨️ “The ultimate goal would be for all patients to receive NGS testing earlier in their disease course," - @chadihcmd of @huntsmancancer told Healio. bit.ly/4lzH2gU
English
0
1
4
225
Chadi Hage Chehade retweetledi
Yüksel Ürün
Yüksel Ürün@DrYukselUrun·
Metformin did not boost survival in metastatic hormone-sensitive prostate cancer. It did ease ADT’s metabolic side effects. Not a game-changer, but still some hope for patient quality of life. #Oncology With very nice editorial by @ggebraelmd @chadihcmd and @neerajaiims @TheLancetOncol @APCCC_Lugano @Silke_Gillessen @Prof_Nick_James @AlisonBirtle @scserendipity1 @AttardLab @drdjmath @mattsydes doi.org/10.1016/S1470-… doi.org/10.1016/S1470-…
Yüksel Ürün tweet media
English
1
22
59
4.3K
Petros Grivas
Petros Grivas@PGrivasMDPhD·
So honored to receive this prestigious award by @eaonc kudos to all investigators/staff who work hard to conduct trials globally! @PrECOGonc @NaomiHaas5 @MonikaJoshimd @JCensits @HutchPresident @nicoleflemingmd @Dr_AmerZeidan @BrainTumorDoc @shilpaonc @OncoAlert @TiansterZhang
Fred Hutch Cancer Center@fredhutch

Congratulations to @PGrivasMDPhD on receiving the 2025 Young Investigator Award from @eaonc! He's recognized for a distinguished record of innovative research, outstanding clinical practice, and unwavering dedication to advancing the field of genitourinary oncology.

English
32
24
160
14.8K